Patients with HER2-positive breast cancer and non-pathologic complete remission have been randomized to adjuvant treatment with trastuzumab deruxtecan or trastuzumab emtansine after neoadjuvant chemotherapy and local therapy in the Destiny Breast 05 study since December 2020. The gene discussed is ERBB2; the disease is breast carcinoma.